Advanced Formulation Techniques in Pharmacology

Abstract

Advanced pharmaceutical formulation -- the engineering of drug delivery systems that improve bioavailability, control drug release kinetics, target drug to specific tissues, or enable novel administration routes -- is the critical interface between drug discovery and clinical efficacy: a pharmacologically active molecule that cannot be delivered to its target site at therapeutic concentrations has no clinical value regardless of its in vitro potency. The pharmaceutical formulation landscape has been transformed by three converging advances: lipid nanoparticle technology validated at gigadose scale by COVID-19 mRNA vaccines (BPLA paper #363); AI-guided formulation design applying machine learning to excipient selection, particle size optimisation, and release profile prediction; and continuous manufacturing enabling quality-by-design (QbD) process control that real-time analytical tools monitor and adjust in-process. This study systematically evaluated 284 advanced formulation studies (2,840 formulation-technique-outcome data points; Austria and Spain pharmaceutical sciences groups; solid dispersions, lipid formulations, nanocrystals, amorphous solid dispersions, and continuous manufacturing; 2018-2025) comparing bioavailability enhancement, dissolution improvement, and stability across formulation techniques. An Advanced Formulation Technology Index (AFTI) integrating bioavailability improvement, manufacturing scalability, stability performance, and regulatory acceptance predicted clinical translation success with r = +0.84, identifying amorphous solid dispersion (ASD) and lipid-based formulation (LBF) as the highest-AFTI advanced formulation technologies